Sutro Biopharma, Inc. (STRO)
After hours:
| Previous close | 3.2900 |
| Open | 3.3200 |
| Bid | 3.4000 x 800 |
| Ask | 3.4100 x 800 |
| Day's range | 3.2450 - 3.4200 |
| 52-week range | 3.2400 - 8.7200 |
| Volume | |
| Avg. volume | 291,504 |
| Market cap | 203.371M |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4400 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.75 |
GlobeNewswireSutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs,
- GlobeNewswire
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Citi 18th Annual BioPharma ConferenceFormat: Fireside ChatDate: Wednesday, September 6, 2023Time: 8:00 a.m. ET / 5:00 a.m. PT Locat
ZacksSutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 12.33% and 0.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
